Current Science

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


Here we compare the in-house ELISA technique for estimation of neuron-specific enolase (NSE) and S-100ββ (glial-specific protein) peptides with a commercial kit in serum samples of acute ischaemic stroke (AIS) patients. Nineteen improved and four expired AIS patients were included for the study. NSE concentrations were significantly higher (P < 0.05) in expired as compared with improved AIS patients by both inhouse ELISA and commercial kit method. Estimation of S-100ββ by only in-house ELISA showed significantly high (P < 0.05) levels in expired AIS patients. Peptide-based estimation of NSE and S-100ββ may be used for prognosis of AIS patients.

Keywords

Acute Ischaemic Stroke, Glial-Specific Protein, Neurological Disease, Neuron-specific Enolase, Prognosis.
User
Notifications
Font Size